Objective: Acute pulmonary embolism (APE) is a serious clinical situation and atrial fibrillation (AF) is the most common arrhytmia in clinical practice. The Pulmonary Embolism Severity Index (PESI) is an accepted risk stratification tool used to predict short term mortality in APE. The aim of this study was to evaluate the relationship between the PESI score and new-onset AF in patients with APE.
A cute pulmonary embolism (APE) is one of the most serious cardiovascular diseases encountered in the emergency department and is associated with a mortality rate of 15% to 20%. [1] The Pulmonary Embolism Severity Index (PESI) is an accepted clinical prognostic score to predict survival in patients with APE. [2] Jiménez et al. [3] developed a simplified version of the PESI (sPESI), based on a study in which they reported that APE patients classified with a low SPESI score had an in-hospital mortality of 1.1% compared to 8.9% in those classified with a high sPESI score.
Atrial fibrillation (AF) is the most commonly sustained cardiac arrhythmia, occurring in 3% of the general population aged 40 years and older. [4] Many clinical conditions, including aging, hypertension, heart failure, valvular heart diseases, cardiomyopathies, congenital cardiac disease, coronary artery disease, thyroid disorders, obesity, diabetes mellitus, chronic obstructive pulmonary disease, sleep apnea, and chronic renal disease, are associated with AF, which in turn may lead to stroke or other thromboembolic events, heart failure, cardiovascular hospitalization, impaired quality of life, or reduced exercise capacity, as well as an increased mortality rate. [5] The potential effect of acute or chronic thromboembolism on the occurrence of AF is controversial and remains unclear. In recent pulmonary thromboembolism guidelines, the relationship between AF and pulmonary thromboembolism (PTE) and the development of AF in patients with PTE are insufficiently addressed. The aim of this study was to evaluate the effect of the severity of acute PTE on the occurrence of AF.
METHODS
Patients admitted to our clinic with suspected APE between May 2012 and December 2015 and had a confirmed diagnosis of APE based on a pulmonary computed tomography angiography or V/Q scintigraphy were enrolled to the study. The following conditions were excluded: hypertension, structural heart disease, hepatic or renal dysfunction, chronic obstructive pulmonary disease, thyroid dysfunction, diabetes mellitus, and sleep apnea. In addition, none of the participants had any history of inflammatory or infectious disease, recent (within the previous 4 weeks) trauma or surgery, or treatment with nonsteroidal anti-inflammatory or corticosteroids drugs. Individuals with missing data in their patient files were also excluded. PESI and sPESI scores were calculated for every patient. According to hospital procedure, echocardiography controls are performed every 3 months to determine any development of chronic thromboembolic pulmonary hypertension. An electrocardiogram (ECG) examination was performed before echocardiography in all patients. SPESI and PESI scores were calculated from the first medical contact data with emergency services.
This retrospective study was conducted in compliance with the principles outlined in the Declaration of Helsinki and the use of data for this retrospective study was allowed by the institutional committee.
A diagnosis of AF and the subsequent treatment were performed according to the European Society of Cardiology guidelines. [5] An episode (defined with irregular RR intervals and distinct P waves) lasting at least 30 seconds on ECG was accepted for the diagnosis of AF. Atrial flutter was classified as part of the AF spectrum for the purpose of the current study. For the diagnosis of new-onset AF, patients who had been treated for AF before the APE diagnosis, and those with hypertension, structural heart disease, a prosthetic heart valve, hepatic or renal dysfunction, chronic obstructive pulmonary disease, thyroid dysfunction, diabetes mellitus, or sleep apnea were excluded. Left ventricle (LV) internal diameters, LV ejection fraction (LVEF; modified Simpson method), left atrial diameter (LAD), tricuspid annular plane systolic excursion (TAPSE), and pulmonary artery systolic pressure (PASP) were measured according to the guidelines of the American Society of Echocardiography. [6] Echocardiography examinations were performed within the first 3 days after diagnosis. 
Continuous variables were expressed as mean±SD

RESULTS
After exclusion of patients not meeting the required criteria, 42 new-onset AF and 107 non-AF patients were included (defined as New AF group and Non-AF group) in the study. The mean follow-up period was 823.6±278.2 days. The time interval between the diagnosis of APE and the diagnosis of AF was 647.7±341.4 days. In the New AF group, the mean age was 63±4 years, and 54.8% were male. In the Non-AF group, the mean age was 59±12 years, and 51.4% were male (Table 1) . No significant differences were observed between the 2 groups regarding age, gender, systolic and diastolic blood pressure, heart rate, or level of fasting glucose or serum creatinine. Uric acid, C-reactive protein and erythrocyte sedimentation rate (p=0.087; p=0.085; p=0.058, respectively) levels were higher in the New-AF patients, but this difference was not statistically significant (Table  2) . New-AF patients had a larger left ventricle end diastolic diameter (LVEDD) and LAD. There was no statistically significant difference between the 2 groups in LVEF, TAPSE, or PASP (p=0.090; p=0.089; p=0.860, respectively).
SPESI scores were higher in the New-AF group, and this difference was statistically significant (p=0.010) ( Table 3 ). Regression analysis indicated that LVEDD, LAD, uric acid, albumin, total bilirubin, and troponin, as well as the PESI and sPESI scores, were univariate predictors of new onset-AF (Table  4) . Multivariate stepwise logistic regression analysis showed that AF was associated with the PESI score, LAD, LVEDD, and levels of alkaline phosphatase and troponin (Table 4 ). The PESI score predicted AF with a sensitivity of 69.0% and specificity of 69.2% in receiver operating characteristic (ROC) curve analysis using a cut-off level of 82.50 (ROC area under curve: 0.721, 95% CI: 0.623-0.818; p<0.001) (Fig.1) .
DISCUSSION
In this study, we found that the PESI score was as- that LVEDD, LAD, and uric acid level were predictors of new AF in the study patients. Impaired LV or left atrial function, and changes in the geometry of the LV and left atrium can trigger AF. This may be why patients with PE develop AF: PE may directly lead to cardiac dysfunctions that trigger AF. The results reported by Hald et al. [7] support this potential mechanism. An increased right atrial pressure may trigger the right atrial remodeling process, leading to the appearance of atrial arrhythmias. However, the findings of our study revealed no significant difference between PASP and TAPSE values between the 2 groups, which does not fully support the hypothesis of atrial arrhythmia due to right ventricular and atrial sociated with new onset AF (New-AF group). A greater PESI score pointed to more serious clinical status in APE, and serious clinical presentation with pulmonary embolism (PE) was associated with newonset AF. The univariate regression results showed dysfunction. In our study, a dilated LA and LV were associated with new-onset AF. Zhang et al. [8] found
an association between serum uric acid level and AF, and Kawasoe et al. [9] also found that uric acid level dictor of in-hospital mortality and 6-month mortality. [12] In our study, the mortality rate of the patients could not be fully assessed because follow-up procedures were performed by another clinic (data were collected from patients of pulmonary clinics).
There are a number of limitations to our study. As it was retrospective in design, data loss in patient follow-up and incomplete information about symptoms may have affected the study results. Obesity status and genetic predisposition of the study population could not be defined. Furthermore, silent AF could not be excluded. Some patients in the non-AF group may have had silent-AF, and these patients could not be identified and excluded. Periods of silent AF may also have affected the time between PTE diagnosis and AF diagnosis in the AF group of patients.
In conclusion, serious clinical status in APE (with a higher sPESI score) was associated with new-onset AF in our study. A PESI score greater than 82.50 may be useful to predict new-onset AF in these patients. The screening for AF after APE may be important to decrease morbidity and mortality specifically related to AF. was significantly associated with AF, independent of other cardiovascular risk factors in 285,882 patients. The result of Kawasoe's study support our findings about a relationship between uric acid and new-onset AF. Uric acid level may be associated with oxidative stress and may be involved in the pathophysiology of AF. In one study, Ng et al. [10] found a prevalence of AF of 13.5% (126/935), but this study was not designed to analyze the prevalence and incidence of new-onset AF in patients with PE. Ng's study and our research determined a similar mean length of time from PE to subsequent AF (3.4±2.9 years; 647.7±341.4 days, respectively). In our study, since patients who had comorbidities that occurred between the time of diagnosis of APE and the diagnosis of AF were excluded, we can accept that new-onset AF was associated with APE. The biomarkers of myocardial injury (troponin) and coagulation activity (D-dimer) have been found to be associated with underlying pathophysiology, the effectiveness of treatment methods, and clinical outcomes in patients with AF. [11] In our study, troponin level was associated with new-onset AF but D-dimer level was not.
AF has been independently associated with an increased risk of all-cause mortality. In a review and meta-analysis, the results indicated that AF is a pre- 
